Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.37B P/E 55.18 EPS this Y -56.90% Ern Qtrly Grth -
Income -7.97M Forward P/E 29.29 EPS next Y - 50D Avg Chg -15.00%
Sales 240.42M PEG 2.00 EPS past 5Y 2.00% 200D Avg Chg -23.00%
Dividend N/A Price/Book 1.71 EPS next 5Y 15.00% 52W High Chg -52.00%
Recommedations 2.00 Quick Ratio 1.26 Shares Outstanding 16.88M 52W Low Chg 12.00%
Insider Own 5.46% ROA 0.81% Shares Float 15.99M Beta 1.10
Inst Own 91.31% ROE -1.00% Shares Shorted/Prior 808.16K/866.74K Price 81.12
Gross Margin 54.49% Profit Margin -3.32% Avg. Volume 117,060 Target Price 179.50
Oper. Margin 6.31% Earnings Date Nov 7 Volume 153,657 Change -0.47%
Ligand Pharmaceuticals Incorpor News
09/14/22 Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
09/13/22 Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
09/07/22 Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?
08/25/22 Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
08/24/22 Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
08/11/22 New Forecasts: Here's What Analysts Think The Future Holds For Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
08/08/22 Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates
08/08/22 Ligand Reports Second Quarter 2022 Financial Results
08/04/22 Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates
08/03/22 Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have endured a 28% loss from investing in the stock five years ago
08/01/22 Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07/22/22 Ligand to Report Second Quarter Financial Results on August 8
07/05/22 Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses
06/29/22 Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
06/09/22 Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
06/03/22 Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?
06/03/22 Zacks.com featured highlights include Ligand Pharmaceuticals, Alarm.com Holdings, Radius Global, ADT, Madison Square Garden
06/02/22 Spot the Red Flags & Sell These 5 Toxic Stocks Right Away
05/18/22 Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

LGND Chatroom

User Image stockilluminati Posted - 23 hours ago

$LGND https://www.stockilluminati.com/lgnd/news.php - Ligand Pharmaceuticals: Struggling Along

User Image Mauisbigtuna Posted - 1 day ago

$LGND Once the insiders and execs who actually know the status start bailing, the end is near.

User Image NedHauck Posted - 2 days ago

$LGND $MMM Incredible list of scans with time frames in each category done by Trade Ideas. Get 17 Months of Trade Ideas for the price of 12 and a 25% off in addition! FOR A LIMITED TIME ONLY via (Google Search)⟶ 𝐭𝐫𝐚𝐝𝐞𝐚𝐥𝐞𝐫𝐭.𝐩𝐰

User Image cctranscripts Posted - 3 days ago

Ligand Pharmaceuticals Incorporated's Chief Executive Officer just disposed of 1,000 shares https://www.conferencecalltranscripts.com/summary/?id=11324731 $LGND

User Image Quantisnow Posted - 3 days ago

$LGND 📜 SEC Form 4: Higgins John L sold $88,060 worth of shares (1,000 units at $88.06), decreasing direct ownership by 0.27% to 366,180 units (Amendment) https://quantisnow.com/i/3445171?utm_source=stocktwits 45 seconds delayed.

User Image Newsfilter Posted - 3 days ago

$LGND Form 4/A (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/61cd108afe02c8d13adc28259d77b49a

User Image BidaskBot Posted - 3 days ago

LigandPharmaceuticals $LGND BidaskScore is Lowered to Sold https://bidaskclub.com/news/company/2022-09-21/LGND

User Image MarketBeat Posted - 5 days ago

Ligand Pharmaceuticals downgraded by StockNews.com to sell. https://www.marketbeat.com/r/1820606 $LGND

User Image InsiderPeek Posted - 1 week ago

$LGND CEO Higgins John L just sold 5k shares for $448.1k (ownership down 1.37%) insiderpeek.com/company/LGND

User Image MarketBeatInsiderTrades Posted - 1 week ago

Ligand Pharmaceuticals CEO John Higgins Sells $180,000.00 in $LGND https://www.marketbeat.com/i/527725

User Image cctranscripts Posted - 1 week ago

Ligand Pharmaceuticals Incorporated's Chief Executive Officer just disposed of 5,000 shares https://www.conferencecalltranscripts.com/summary/?id=11308505 $LGND

User Image Quantisnow Posted - 1 week ago

$LGND 📜 SEC Form 4: Higgins John L sold $448,050 worth of shares (5,000 units at $89.61), decreasing direct ownership by 1% to 364,180 units https://quantisnow.com/i/3423204?utm_source=stocktwits ⚡ See this insight 45 seconds early at https://quantisnow.com/feed ⚡

User Image risenhoover Posted - 1 week ago

Insider John L Higgins reports selling 5,000 shares of $LGND for a total cost of $448,050.00 https://fintel.io/n/us/lgnd/higgins-john-l?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image Newsfilter Posted - 1 week ago

$LGND Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/acac0f4ebc7cffb49ebc4a3398505f0d

User Image NoOriginality Posted - 1 week ago

$LGND Picked up some shares at $86.40.

User Image WindyCityGuy Posted - 1 week ago

$NEXI one piece of real news sends this 5x plus Low float cancer stock in phase 1 w cash heavily shorted. It's early but 52 week low in. @ $ATOS $BEAM $LGND

User Image fla Posted - 1 week ago

$LGND [15s. delayed]: Issued Press Release on September 14, 11:22:00: Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable https://s.flashalert.me/mLBfi

User Image Quantisnow Posted - 1 week ago

$LGND 📰 Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen https://quantisnow.com/i/3411140?utm_source=stocktwits 45 seconds delayed.

User Image Newsfilter Posted - 1 week ago

$LGND Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor .. https://newsfilter.io/a/5c477f9a5d064291bf538b1898ef41e9

User Image fla Posted - 1 week ago

$LGND [15s. delayed]: Issued Press Release on September 13, 09:00:00: Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasof https://s.flashalert.me/iLJaGz

User Image Quantisnow Posted - 1 week ago

$LGND 📰 Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation https://quantisnow.com/i/3404263?utm_source=stocktwits 45 seconds delayed.

User Image Newsfilter Posted - 1 week ago

$LGND Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutati.. https://newsfilter.io/a/a48bd4c5aa17acbd54836cc4bf2f480f

User Image BidaskBot Posted - 2 weeks ago

LigandPharmaceuticals $LGND BidaskScore is #Reiterated to Held https://bidaskclub.com/news/company/2022-09-08/LGND

User Image EarningsInsider Posted - 2 weeks ago

$LGND updates FY 2022 guidance to $2.40-$3.00 EPS and revenue guidance to $169.00 million-$188.00 million. https://www.marketbeat.com/g/112

User Image stocktargetadvisors Posted - 3 weeks ago

$LGND latest rating from Roth Capital on 2022-09-02, setting target price at: USD 175.00 with a rating of Buy. StockTargetAdvisor's own view is Slightly Bullish with an average target price of USD 149.00. Details: https://www.stocktargetadvisor.com/stock/USA/NSD/LGND

User Image Newsfilter Posted - 3 weeks ago

$LGND Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals with a Buy and lowers the price target from $185 to $175.

User Image MarketBeat Posted - 3 weeks ago

Ligand Pharmaceuticals's PT cut by Roth Capital to $175.00. https://www.marketbeat.com/r/1815247 $LGND

User Image macroaxis Posted - 3 weeks ago

$LGND - Risk alert: Ligand Pharm maximum pain price is depinning https://www.macroaxis.com/stock-options/LGND/Ligand-Pharm?utm_source=dlvr.it&utm_medium=stocktwits

User Image Invescent Posted - 3 weeks ago

Overall A has given $LGND Buy Rating . When analysing the financial scores the results are as followed: PiotroskiScore: 8.0 Rating Score: 4 DCF Score 5 ROA Score: 3 PB Score : 5 PE Score: 5 Simplify the way you do research and look for stocks with Invescent https://play.google.com/store/apps/details?id=org.invescentpro.invescent

User Image SweepCast Posted - 08/31/22

@SweepCast Unusual Options Observed: $LGND with our scanner on $130 PUT Expiring: 02-17-2023 worth 35K🐻 ⬅️ The Flow of Smart Money Options Is Critical - See Profile for More Info 🏆

Analyst Ratings
Roth Capital Buy Sep 2, 22
Barclays Overweight Jul 5, 22
Stephens & Co. Overweight May 16, 22
Benchmark Buy Feb 22, 22
Barclays Overweight Feb 18, 22
Barclays Overweight Sep 22, 21
Roth Capital Buy Jul 30, 21
Barclays Overweight May 4, 21
Barclays Overweight Feb 4, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Sep 16 Sell 88.06 1,000 88,060 366,180 09/22/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Sep 15 Sell 89.68 5,000 448,400 364,180 09/16/22
FOEHR MATTHEW W President and COO President and COO May 13 Buy 82.7638 2,500 206,910 173,354 05/13/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer May 09 Option 21.92 8,000 175,360 348,593 05/10/22
KOZARICH JOHN W Director Director May 13 Option 10.12 4,835 48,930 34,543 05/13/21
Davis Todd C Director Director Feb 12 Option 195.91 2,474 484,681 50,152 02/12/21
Davis Todd C Director Director Feb 12 Sell 213.14 5,083 1,083,391 47,678 02/12/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Feb 09 Option 12.26 114,666 1,405,805 346,030 02/09/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Feb 09 Sell 203.4 54,666 11,119,064 286,030 02/09/21
Berkman Charles S SVP, Gen. Counsel &.. SVP, Gen. Counsel & Secretary Feb 05 Sell 178.5 18,097 3,230,314 28,906 02/05/21
FOEHR MATTHEW W President and COO President and COO Feb 05 Option 48.17 45,547 2,193,999 212,745 02/05/21
FOEHR MATTHEW W President and COO President and COO Feb 05 Sell 176.86 44,547 7,878,582 168,198 02/05/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Jan 27 Option 16.95 120,000 2,034,000 273,422 01/27/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Jan 27 Sell 170.5 90,000 15,345,000 243,422 01/27/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Dec 09 Option 10.05 14,657 147,303 236,770 12/09/20
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Nov 10 Option 10.05 20,000 201,000 224,571 11/10/20